The impact of clonal evolution on response to imatinib mesylate (STI571) in accelerated phase CML

Michael E. O'Dwyer, Michael J. Mauro, Gwen Kurilik, Motomi (Tomi) Mori, Suzanne Balleisen, Susan Olson, Ellen Magenis, Renaud Capdeville, Brian Druker

Research output: Contribution to journalArticle

110 Citations (Scopus)

Abstract

In chronic myelogenous leukemia (CML), the development of chromosomal abnormalities in addition to the Philadelphia chromosome (clonal evolution) is considered by many to be a feature of accelerated phase (AP). Imatinib mesylate (STI571), a selective inhibitor of the Bcr-Abl tyrosine kinase, has significant activity in AP CML. As clonal evolution could allow Bcr-Abl independent proliferation, we analyzed its impact on the outcome of 71 AP patients treated with 600 mg of imatinib mesylate. Fifteen patients had clonal evolution alone (AP-CE), 32 had AP features but no evidence of clonal evolution (HEM-AP), and 24 had AP features plus clonal evolution (HEM-AP + CE). Of the AP-CE patients, 73% had a major cytogenetic response, compared with 31% of the HEM-AP patients (P = .043) and 12.5% of the HEM-AP + CE patients (P = .007). Complete cytogenetic responses were seen in 60% of AP-CE patients, compared with 31% of HEM-AP patients (P = .19) and 8% of HEM-AP + CE patients (P <.001). With mean follow-up of 11.2 months, 35% of all patients failed treatment. The lowest estimated rate of treatment failure at 1 year, 0%, was seen in AP-CE patients, compared with rates of 31% for HEM-AP patients and 69% for HEM-AP + CE patients (P = .0004). After 1 year, 100% of AP-CE patients were still alive, compared with 85% of HEM-AP patients and 67.5% of HEM-AP + CE patients (P = .01). In conclusion, in patients with clonal evolution as the sole criterion of disease acceleration, good responses to imatinib are still possible. Once patients have other signs of acceleration, clonal evolution predicts lower response rates and a shorter time to treatment failure.

Original languageEnglish (US)
Pages (from-to)1628-1633
Number of pages6
JournalBlood
Volume100
Issue number5
DOIs
StatePublished - Sep 1 2002

Fingerprint

Clonal Evolution
Leukemia, Myeloid, Chronic Phase
bcr-abl Fusion Proteins
Patient treatment
Chromosomes
Imatinib Mesylate
Treatment Failure
Cytogenetics
Philadelphia Chromosome

ASJC Scopus subject areas

  • Hematology

Cite this

The impact of clonal evolution on response to imatinib mesylate (STI571) in accelerated phase CML. / O'Dwyer, Michael E.; Mauro, Michael J.; Kurilik, Gwen; Mori, Motomi (Tomi); Balleisen, Suzanne; Olson, Susan; Magenis, Ellen; Capdeville, Renaud; Druker, Brian.

In: Blood, Vol. 100, No. 5, 01.09.2002, p. 1628-1633.

Research output: Contribution to journalArticle

O'Dwyer, ME, Mauro, MJ, Kurilik, G, Mori, MT, Balleisen, S, Olson, S, Magenis, E, Capdeville, R & Druker, B 2002, 'The impact of clonal evolution on response to imatinib mesylate (STI571) in accelerated phase CML', Blood, vol. 100, no. 5, pp. 1628-1633. https://doi.org/10.1182/blood-2002-03-0777
O'Dwyer, Michael E. ; Mauro, Michael J. ; Kurilik, Gwen ; Mori, Motomi (Tomi) ; Balleisen, Suzanne ; Olson, Susan ; Magenis, Ellen ; Capdeville, Renaud ; Druker, Brian. / The impact of clonal evolution on response to imatinib mesylate (STI571) in accelerated phase CML. In: Blood. 2002 ; Vol. 100, No. 5. pp. 1628-1633.
@article{c2e561bba5874bcda9a2c114d8eaf991,
title = "The impact of clonal evolution on response to imatinib mesylate (STI571) in accelerated phase CML",
abstract = "In chronic myelogenous leukemia (CML), the development of chromosomal abnormalities in addition to the Philadelphia chromosome (clonal evolution) is considered by many to be a feature of accelerated phase (AP). Imatinib mesylate (STI571), a selective inhibitor of the Bcr-Abl tyrosine kinase, has significant activity in AP CML. As clonal evolution could allow Bcr-Abl independent proliferation, we analyzed its impact on the outcome of 71 AP patients treated with 600 mg of imatinib mesylate. Fifteen patients had clonal evolution alone (AP-CE), 32 had AP features but no evidence of clonal evolution (HEM-AP), and 24 had AP features plus clonal evolution (HEM-AP + CE). Of the AP-CE patients, 73{\%} had a major cytogenetic response, compared with 31{\%} of the HEM-AP patients (P = .043) and 12.5{\%} of the HEM-AP + CE patients (P = .007). Complete cytogenetic responses were seen in 60{\%} of AP-CE patients, compared with 31{\%} of HEM-AP patients (P = .19) and 8{\%} of HEM-AP + CE patients (P <.001). With mean follow-up of 11.2 months, 35{\%} of all patients failed treatment. The lowest estimated rate of treatment failure at 1 year, 0{\%}, was seen in AP-CE patients, compared with rates of 31{\%} for HEM-AP patients and 69{\%} for HEM-AP + CE patients (P = .0004). After 1 year, 100{\%} of AP-CE patients were still alive, compared with 85{\%} of HEM-AP patients and 67.5{\%} of HEM-AP + CE patients (P = .01). In conclusion, in patients with clonal evolution as the sole criterion of disease acceleration, good responses to imatinib are still possible. Once patients have other signs of acceleration, clonal evolution predicts lower response rates and a shorter time to treatment failure.",
author = "O'Dwyer, {Michael E.} and Mauro, {Michael J.} and Gwen Kurilik and Mori, {Motomi (Tomi)} and Suzanne Balleisen and Susan Olson and Ellen Magenis and Renaud Capdeville and Brian Druker",
year = "2002",
month = "9",
day = "1",
doi = "10.1182/blood-2002-03-0777",
language = "English (US)",
volume = "100",
pages = "1628--1633",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "5",

}

TY - JOUR

T1 - The impact of clonal evolution on response to imatinib mesylate (STI571) in accelerated phase CML

AU - O'Dwyer, Michael E.

AU - Mauro, Michael J.

AU - Kurilik, Gwen

AU - Mori, Motomi (Tomi)

AU - Balleisen, Suzanne

AU - Olson, Susan

AU - Magenis, Ellen

AU - Capdeville, Renaud

AU - Druker, Brian

PY - 2002/9/1

Y1 - 2002/9/1

N2 - In chronic myelogenous leukemia (CML), the development of chromosomal abnormalities in addition to the Philadelphia chromosome (clonal evolution) is considered by many to be a feature of accelerated phase (AP). Imatinib mesylate (STI571), a selective inhibitor of the Bcr-Abl tyrosine kinase, has significant activity in AP CML. As clonal evolution could allow Bcr-Abl independent proliferation, we analyzed its impact on the outcome of 71 AP patients treated with 600 mg of imatinib mesylate. Fifteen patients had clonal evolution alone (AP-CE), 32 had AP features but no evidence of clonal evolution (HEM-AP), and 24 had AP features plus clonal evolution (HEM-AP + CE). Of the AP-CE patients, 73% had a major cytogenetic response, compared with 31% of the HEM-AP patients (P = .043) and 12.5% of the HEM-AP + CE patients (P = .007). Complete cytogenetic responses were seen in 60% of AP-CE patients, compared with 31% of HEM-AP patients (P = .19) and 8% of HEM-AP + CE patients (P <.001). With mean follow-up of 11.2 months, 35% of all patients failed treatment. The lowest estimated rate of treatment failure at 1 year, 0%, was seen in AP-CE patients, compared with rates of 31% for HEM-AP patients and 69% for HEM-AP + CE patients (P = .0004). After 1 year, 100% of AP-CE patients were still alive, compared with 85% of HEM-AP patients and 67.5% of HEM-AP + CE patients (P = .01). In conclusion, in patients with clonal evolution as the sole criterion of disease acceleration, good responses to imatinib are still possible. Once patients have other signs of acceleration, clonal evolution predicts lower response rates and a shorter time to treatment failure.

AB - In chronic myelogenous leukemia (CML), the development of chromosomal abnormalities in addition to the Philadelphia chromosome (clonal evolution) is considered by many to be a feature of accelerated phase (AP). Imatinib mesylate (STI571), a selective inhibitor of the Bcr-Abl tyrosine kinase, has significant activity in AP CML. As clonal evolution could allow Bcr-Abl independent proliferation, we analyzed its impact on the outcome of 71 AP patients treated with 600 mg of imatinib mesylate. Fifteen patients had clonal evolution alone (AP-CE), 32 had AP features but no evidence of clonal evolution (HEM-AP), and 24 had AP features plus clonal evolution (HEM-AP + CE). Of the AP-CE patients, 73% had a major cytogenetic response, compared with 31% of the HEM-AP patients (P = .043) and 12.5% of the HEM-AP + CE patients (P = .007). Complete cytogenetic responses were seen in 60% of AP-CE patients, compared with 31% of HEM-AP patients (P = .19) and 8% of HEM-AP + CE patients (P <.001). With mean follow-up of 11.2 months, 35% of all patients failed treatment. The lowest estimated rate of treatment failure at 1 year, 0%, was seen in AP-CE patients, compared with rates of 31% for HEM-AP patients and 69% for HEM-AP + CE patients (P = .0004). After 1 year, 100% of AP-CE patients were still alive, compared with 85% of HEM-AP patients and 67.5% of HEM-AP + CE patients (P = .01). In conclusion, in patients with clonal evolution as the sole criterion of disease acceleration, good responses to imatinib are still possible. Once patients have other signs of acceleration, clonal evolution predicts lower response rates and a shorter time to treatment failure.

UR - http://www.scopus.com/inward/record.url?scp=0036720397&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036720397&partnerID=8YFLogxK

U2 - 10.1182/blood-2002-03-0777

DO - 10.1182/blood-2002-03-0777

M3 - Article

VL - 100

SP - 1628

EP - 1633

JO - Blood

JF - Blood

SN - 0006-4971

IS - 5

ER -